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(range: 5–20). In 75% of symptomatic patients catheterization, have been described 90–100% stenosis of at least one artery. The
anterior descending branch was affected in 70% of such patients.
Objetives. The heart is an organ at risk incorrectly deﬁned today as a solid organ. Since it is the anterior wall of the VI which
receive 50% or more of the dose, we think the proper contouring of the left coronary artery and its branches, as well as the
left ventricular wall, embryological, histological, anatomical and functionally compromised structures that should be taken into
account when a correct delimitation it is done, key aspect in reducing the long-term cardiac events produced in breast cancer
patients treated with radiotherapy.
Methods.We brieﬂy reviewall aspects of normal left ventricular structure and Standardizedmyocardial segmentation andnomen-
clature for tomographic imaging of the heart of American Heart Association. We outline the whole heart (A), the heart with its
four chambers (B), only the left ventricle (C) and anterior descending coronary artery in ﬁve women, which had been made a CT
with IV contrast for radiotherapy planning of esophageal carcinoma. We compared the maximum, minimum, mean dose, Vx.
Results. All doses vary signiﬁcantly if we outline in the ways previously mentioned, being the most anatomically correct LV
sole contouring although dose unfavorable. With the delineation of anterior descending coronary proximal, middle and distal,
maximum, mean and minimum doses were similar. The anterior descending coronary 65% of its length receives more than 50%
of the dose.
Conclusions. The correct contouring should be limited to cardiac anterior wall of the left ventricle and the coronary artery, the
conformation of the ﬁelds, the techniquewill be oriented to themaximumpreservation of these two structures. Note the probably
damage of cardiac stem cells source at epicardium, and therefore the possible regenerative cell therapy for myocardial injury
and the formation coronary vessels.
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Introduction. Standard fractionation RT is widely used for breast cancer treatments. Nevertheless, the same level of efﬁcacy and
security has been demonstrated with altered fractionations in terms of local control and toxicity rates. Goals: Evaluation of acute
tolerance, late effects, and efﬁcacy of hypofractionated treatments on breast cancer patients.
Material and methods. From February 2012, seventeen breast cancer patients staged pT1-T2, N0-1, M0 have received 3D planned
adjuvant radiotherapy with a fractionation schedule of 15 fractions of 2.67Gy up to a total dose of 40Gy during three weeks after
tumorectomy, sentinel node biopsy or axillary node dissection (2 patients). Two patients received a boost on the surgical bed
subsequently. Weekly consultations during treatment have been performed in order to evaluate treatment tolerance.
Results. Mean age was 67.5 y.o. (50–84). Stage distribution was 68.7% stage I and 31.7% stage II. Most patients had Inﬁltrating
Ductal Carcinoma (75%), followed by Inﬁltrating Lobular Carcinoma (18,7%) and Mucinous Carcinoma (6,2%). Histologic grade
was % Grade I (56.2%), Grade II (37.5%) or Grade III (6.2%). Two patients received adjuvant chemotherapy whereas the whole
group has received hormonal treatments. Cutaneous toxicity, graded with RTOG scale, grade 1 (43.7%), and grade 2 (12.5%). No
grade 3 radiodermatitis has been observed.
Conclusion. Hypofractionated adjuvant breast irradiation allows the shortage of the radiotherapy course without an increment in
the cutaneous toxicity burden. The study is progressing in order to asses the local control rates and late effects.
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Introduction. In February 2012 the project LIFE (INNPRONTA) is approved by the Council ofMinisters at the request of the CDTI. This
program represents a qualitative leap in R & D collaboration between ﬁrms and research organizations. Companies participating
in the LIFE project are: ERESA (consortium leader), Genome Systems, Gem-Imaging, IUCT, Instituto Cartuja, Proton Bilbomática
and Laser Applications.
